BridgeMD
A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's disease dementia
EU CTIS ID: 2024-517388-22-00
What this study is testing
To evaluate the therapeutic change from baseline of EXV-802 compared with placebo in the treatment of agitation.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker, or with a wheelchair.
- A previously established diagnosis of AD dementia.
- The participant meets definition for agitation which require treatment with medicines.
- The severity of agitation is at least moderate.
You likely can't join if
- The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia.
- The participant has symptoms of agitation that are due to psychiatric conditions other than AD dementia.
- The participant has a history of uncontrolled seizures or a history of epilepsy.
- The participant lacks a caregiver or support person who attends regularly to the participants’ needs.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.